Research/art/teacher profile of a person
Name and surname:
MUDr. Jana Obertová, PhD.
Document type:
Research/art/teacher profile of a person
The name of the university:
Comenius University Bratislava
The seat of the university:
Šafárikovo námestie 6, 818 06 Bratislava

I. - Basic information

I.1 - Surname
Obertova
I.2 - Name
Jana
I.3 - Degrees
M.D., PhD.
I.4 - Year of birth
1970
I.5 - Name of the workplace
2nd Department of Oncology
I.6 - Address of the workplace
Klenova 1, 833 10 Bratislava
I.7 - Position
Assistant Professor
I.8 - E-mail address
jobert878@gmail.com
I.9 - Hyperlink to the entry of a person in the Register of university staff
https://www.portalvs.sk/regzam/detail/5379
I.10 - Name of the study field in which a person works at the university
Oncology
I.11 - ORCID iD
0000-0002-7216-4843

II. - Higher education and further qualification growth

II.1 - First degree of higher education
II.2 - Second degree of higher education
II.a - Name of the university or institution
Faculty of Medicine, Comenius University in Bratislava
II.b - Year
1994
II.c - Study field and programme
General Medicine
II.3 - Third degree of higher education
II.a - Name of the university or institution
Faculty of Medicine, Comenius University in Bratislava
II.b - Year
2013
II.c - Study field and programme
Oncology
II.4 - Associate professor
II.5 - Professor
II.6 - Doctor of Science (DrSc.)

III. - Current and previous employment

III.a - Occupation-position III.b - Institution III.c - Duration
Assistant Professor Faculty of Medicine, Comenius University in Bratislava 2008 - until now
Medical Oncologist National Cancer Institute 2001 - until now
Specialist in Internal Medicine National Cancer Institute 1998 - until now
Medical Fellow National Cancer Institute 1995 - 1998

IV. - Development of pedagogical, professional, language, digital and other skills

IV.a - Activity description, course name, other IV.b - Name of the institution IV.c - Year
Board Certification from Medical Oncology (II. degreee) Slovak Medical University, Bratislava 2001
Board Certification from Internal Medicine (I. degree) Slovak Medical University, Bratislava 1998

V. - Overview of activities within the teaching career at the university

V.1 - Overview of the profile courses taught in the current academic year according to study programmes
V.1.a - Name of the profile course V.1.b - Study programme V.1.c - Degree V.1.d - Field of study
Internal Medicine (Oncology) General Medicine I.+II. General Medicine
V.2 - Overview of the responsibility for the delivery, development and quality assurance of the study programme or its part at the university in the current academic year
V.3 - Overview of the responsibility for the development and quality of the field of habilitation procedure and inaugural procedure in the current academic year
V.4 - Overview of supervised final theses
V.4.1 - Number of currently supervised theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
1/2
V.4.c - Dissertation (third degree)
0
V.4.2 - Number of defended theses
V.4.a - Bachelor's (first degree)
0
V.4.b - Diploma (second degree)
8/11
V.4.c - Dissertation (third degree)
0
V.5 - Overview of other courses taught in the current academic year according to study programmes
V.5.a - Name of the course V.5.b - Study programme V.5.c - Degree V.5.d - Field of study
Socially Important Malignancies General Medicine I.+II. General Medicine

VI. - Overview of the research/artistic/other outputs

VI.1 - Overview of the research/artistic/other outputs and the corresponding citations
VI.1.1 - Number of the research/artistic/other outputs
VI.1.a - Overall
47
VI.1.b - Over the last six years
30
VI.1.2 - Number of the research/artistic/other outputs registered in the Web of Science or Scopus databases
VI.1.a - Overall
42
VI.1.b - Over the last six years
28
VI.1.3 - Number of citations corresponding to the research/artistic/other outputs
VI.1.a - Overall
300
VI.1.b - Over the last six years
200
VI.1.4 - Number of citations registered in the Web of Science or Scopus databases
VI.1.a - Overall
280
VI.1.b - Over the last six years
178
VI.1.5 - Number of invited lectures at the international, national level
VI.1.a - Overall
0
VI.1.b - Over the last six years
0
VI.2 - The most significant research/artistic/other outputs
1

Slopovsky J, Kucharska J, Obertova J, Mego M, Kalavska K, Cingelova S, Svetlovska D, Gvozdjakova A, Furka S, Palacka P. Plasma thiobarbituric acid reactive substances predict survival in chemotherapy naïve patients with metastatic urothelial carcinoma. Transl Oncol 2021; 14(1): 1-6. IF 4.803

2

Palacka P, Slopovsky J, Obertova J, Chovanec M, Rejlekova K, Sycova-Mila Z, Kollarik B, Mardiak J, Mego M. Survival prediction by baseline systemic immune-inflammation index and its changes during first-line platinum-based treatment in a Caucasian population of patients with metastatic urothelial carcinoma. Anticancer Res 2021; 41(11): 5749-5759. IF 2.435

3

Palacka P, Gvozdjáková A, Rausová Z, Kucharská J, Slopovský J, Obertová J, Furka D, Furka S, Singh KK, Sumbalová Z. Platelet mitochondrial bioenergetics reprogramming in patients with urothelial carcinoma. Int J Mol Sci 2021; 23(1): 1-21. IF 5.6

4

Chovanec M, Kalavska K, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z, Orszaghova Z, Lesko P, De Angelis V, Vasilkova L, Svetlovska D, Mladosievicova B, Mardiak J, Pastorek M, Vlkova B, Celec P, Mego M. Cognitive impairment and biomarkers of gut microbial translocation in testicular germ cell tumor survivors. Front Oncol. 2023 Mar 21;13:1146032. doi: 10.3389/fonc.2023.1146032. PMID: 37025582; PMCID: PMC10070731.

5

Palacka P, Kucharská J, Obertová J, Rejleková K, Slopovský J, Mego M, Světlovská D, Kollárik B, Mardiak J, Gvozdjáková A. Changes in CoQ10/lipids ratio, oxidative stress, and coenzyme Q10 during first-line cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma. Int J Mol Sci 2022; 23(21): 1-17. IF 5.6

VI.3 - The most significant research/artistic/other outputs over the last six years
1

Slopovsky J, Kucharska J, Obertova J, Mego M, Kalavska K, Cingelova S, Svetlovska D, Gvozdjakova A, Furka S, Palacka P. Plasma thiobarbituric acid reactive substances predict survival in chemotherapy naïve patients with metastatic urothelial carcinoma. Transl Oncol 2021; 14(1): 1-6. IF 4.803

2

Palacka P, Slopovsky J, Obertova J, Chovanec M, Rejlekova K, Sycova-Mila Z, Kollarik B, Mardiak J, Mego M. Survival prediction by baseline systemic immune-inflammation index and its changes during first-line platinum-based treatment in a Caucasian population of patients with metastatic urothelial carcinoma. Anticancer Res 2021; 41(11): 5749-5759. IF 2.435

3

Palacka P, Gvozdjáková A, Rausová Z, Kucharská J, Slopovský J, Obertová J, Furka D, Furka S, Singh KK, Sumbalová Z. Platelet mitochondrial bioenergetics reprogramming in patients with urothelial carcinoma. Int J Mol Sci 2021; 23(1): 1-21. IF 5.6

4

Chovanec M, Kalavska K, Obertova J, Palacka P, Rejlekova K, Sycova-Mila Z, Orszaghova Z, Lesko P, De Angelis V, Vasilkova L, Svetlovska D, Mladosievicova B, Mardiak J, Pastorek M, Vlkova B, Celec P, Mego M. Cognitive impairment and biomarkers of gut microbial translocation in testicular germ cell tumor survivors. Front Oncol. 2023 Mar 21;13:1146032. doi: 10.3389/fonc.2023.1146032. PMID: 37025582; PMCID: PMC10070731.

5

Palacka P, Kucharská J, Obertová J, Rejleková K, Slopovský J, Mego M, Světlovská D, Kollárik B, Mardiak J, Gvozdjáková A. Changes in CoQ10/lipids ratio, oxidative stress, and coenzyme Q10 during first-line cisplatin-based chemotherapy in patients with metastatic urothelial carcinoma. Int J Mol Sci 2022; 23(21): 1-17. IF 5.6

VI.4 - The most significant citations corresponding to the research/artistic/other outputs
1

Palacka P, Mego M, Obertová J, Chovanec M, Syčová-Milá Z, Mardiak J. First Slovak experience with second-line vinflunine in advanced urothelial carcinomas. Klinická onkologie 2014;27(6): 429-433.


Citácia: Passalacqua R et al.: BMC Cancer, vol. 17, no. 1, 2017, art. no. 493 -- SCI; SCOPUS

2

Palacka P, Slopovsky J, Obertova J, Chovanec M, Rejlekova K, Sycova-Mila Z, Kollarik B, Mardiak J, Mego M. Survival prediction by baseline systemic immune-inflammation index and its changes during first-line platinum-based treatment in a Caucasian population of patients with metastatic urothelial carcinoma. Anticancer Res 2021; 41(11): 5749-5759.


Citácia: Li J et al. Frontiers in Immunology, vol. 13, 2022, art. no. 865643 -- SCI; SCOPUS

3

Slopovsky J, Kucharska J, Obertova J, Mego M, Kalavska K, Cingelova S, Svetlovska D, Gvozdjakova A, Furka S, Palacka P. Plasma thiobarbituric acid reactive substances predicts survival in chemotherapy naïve patients with metastatic urothelial carcinoma. Transl Oncol 2021; 14(1): 1-6.


Citácia: Liu JY et al. European Journal of Medical Research, vol. 28, no. 1, 2023, art. no. 469 -- SCI ; SCOPUS

4

Palacka P, Gvozdjáková A, Rausová Z, Kucharská J, Slopovský J, Obertová J, Furka D, Furka S, Singh KK, Sumbalová Z. Platelet mitochondrial bioenergetics reprogramming in patients with urothelial carcinoma. Int J Mol Sci 2021; 23(1): 1-21.


Citácia: Chen LL et al. Frontiers in Oncology, vol. 13, 2023, art.no. 1121401 -- SCI; SCOPUS

5

Palacka P, Gvozdjáková A, Rausová Z, Kucharská J, Slopovský J, Obertová J, Furka D, Furka S, Singh KK, Sumbalová Z. Platelet mitochondrial bioenergetics reprogramming in patients with urothelial carcinoma. Int J Mol Sci 2021; 23(1): 1-21.


Citácia: Teng Y: International Journal of Molecular Sciences, vol. 24, no. 9, 2023, art. no. 7693 -- SCI; SCOPUS

VI.5 - Participation in conducting (leading) the most important research projects or art projects over the last six years
1

Identification and validation of biomarkers and underlying molecular pathways of late toxicity of curative treatment in testicular germ cell tumours.

Position: SI.

APVV-19-0411


2

Identification of biomarkers associated with late toxicity of chemotherapy in testicular germ cell tumours.

Position: SI.

APVV-15-0086

VII. - Overview of organizational experience related to higher education and research/artistic/other activities

VII.a - Activity, position VII.b - Name of the institution, board VII.c - Duration
Supervising and rewieving of specialization theses Faculty of Medicine, Comenius University in Bratislava 2008 - until now

VIII. - Overview of international mobilities and visits oriented on education and research/artistic/other activities in the given field of study

VIII.a - Name of the institution VIII.b - Address of the institution VIII.c - Duration (indicate the duration of stay) VIII.d - Mobility scheme, employment contract, other (describe)
University of Naples Federico II - Faculty of Medicine Neapol 1993 observership

IX. - Other relevant facts

IX.a - If relevant, other activities related to higher education or research/artistic/other activities are mentioned

Membership: Slovak Oncology Society (SOS)

Date of last update
2024-04-25